Please assess the completion status of the following clinical trial:

Trial Title: Study of VESIcare® In Overactive Bladder (OAB) Subjects to Evaluate Symptom Bother and Health Related Quality of Life

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ambulatory male or female subject ≥ 18 years of age and able to use the toilet without difficulty~* History of OAB symptoms for ≥ 3 months~* An average of ≥ 8 micturitions per 24 hours and ≥ 1 urgency episode (with or without incontinence) per 24 hours as documented in a 3-day micturition diary~* Subjects are bothered by symptoms as reflected by PPBC ≥3~Exclusion Criteria:~* Evidence of chronic urologic inflammation such as interstitial cystitis and bladder stones; uncontrolled narrow angle glaucoma; urinary or gastric retention~* Recurrent urinary tract infection (UTI) of \> 3 episodes within the last 3 months or evidence of a urinary tract infection at Baseline Visit (Visit 2)~* Significant stress incontinence or mixed stress/urge incontinence where stress is the predominant factor as determined by the investigator~* History of renal or hepatic impairment(2 x Upper Limit of Normal(ULN) values in parameters and considered clinically significant by the investigator~* History of diagnosed gastrointestinal obstruction disease~* Subject has a known diagnosis or history of carcinoma (including prostate cancer) except non metastatic basal or squamous cell carcinoma of the skin that has been successfully treated or previous pelvis radiation within the past five years~* Known or suspected hypersensitivity to solifenacin succinate, any components, or other anticholinergics

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: ACTIVE_COMPARATOR): Matching placebo tablet taken once daily
- Solifenacin Succinate (Type: EXPERIMENTAL): 5mg or 10mg tablet taken once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).